StockData
Tonix Pharmaceuticals Holding Corp. logo

Tonix Pharmaceuticals Holding Corp. (TNXP) stock

TNXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3086% below fair value
$2.38−0.17 (-6.67%)

Close on Nov 20, 2026Market cap $40.82MP/E –Yield –

Tonix Pharmaceuticals revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Tonix Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $29.10M, up 196.0% year over year. For fiscal 2025 it was $13.11M, up 29.8% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$13.11M+29.8%
FY2024Dec 31, 2024$10.09M+29.9%
FY2023Dec 31, 2023$7.77M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$13.54M+577.9%
Q1 FY2026Mar 31, 2026$6.88M+183.2%
Q4 FY2025Dec 31, 2025$5.39M+108.8%
Q3 FY2025Sep 30, 2025$3.29M+16.6%
Q2 FY2025Jun 30, 2025$2.00M-9.5%
Q1 FY2025Mar 31, 2025$2.43M-2.1%
Q4 FY2024Dec 31, 2024$2.58M-31.7%
Q3 FY2024Sep 30, 2024$2.82M-29.3%
Q2 FY2024Jun 30, 2024$2.21M–
Q1 FY2024Mar 31, 2024$2.48M–
Q4 FY2023Dec 31, 2023$3.78M–
Q3 FY2023Sep 30, 2023$3.99M–

More Tonix Pharmaceuticals figures

See a number that looks wrong?